<DOC>
	<DOC>NCT02062255</DOC>
	<brief_summary>Obesity promotes worse outcome for post-menopausal breast cancer patients.</brief_summary>
	<brief_title>Impact of COX2 on Sera Biomarkers From Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>At least 18 years of age Postmenopausal as confirmed by medical history Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee Evidence of active cancer (patients with a prior history of malignancy are encouraged to participate, but due to cytokine levels associated with malignancy there must be no evidence of disease) Cachexia Active systemic illness (infection including viral illnesses such as Hepatitis and HIV) Chronic use of aspirin of omega3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days) Known hypersensitivity to aspirin and/or omega3 fatty acids Actively receiving a physiciandirected regimen of aspirin and/or receiving herapeutic/prophylactic anticoagulation Any aspirin or omega3 free fatty acid supplementation within the last 14 days Subjects who are pregnant History of medical noncompliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asprin</keyword>
	<keyword>Omega-3 Free Fatty Acids</keyword>
	<keyword>Obesity</keyword>
	<keyword>COX-2 inhibitor</keyword>
</DOC>